Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New breathing therapy shows promise for Long-COVID breathlessness

NCT ID NCT06503913

Symptom relief Sponsor: University of Salford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a therapy called Cognitive Muscular Therapy (CMT) for people with Long-COVID who have trouble breathing. CMT combines breathing retraining with techniques to reduce overactive muscles that can interfere with breathing. 18 adults with moderate to severe breathlessness took part. The goal was to see if CMT could reduce breathlessness and improve overall well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cognitive Muscular Therapy (a type of physiotherapy that retrains breathing and reduces overactive postural muscles)
What this could lead to
If it works, this could offer a non-drug way to manage breathlessness in people with Long-COVID.
What could go wrong
This was a very small study (18 people) with no control group, so results may not apply widely. The therapy is also new and needs more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Aug 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Above 18 years old * Experience moderate/severe breathlessness, quantified using the Modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) scale. * Speak and understand English sufficiently to read the information sheet and sign the consent form * Ability to stand without any assistive device for at least 20 minutes (to ensure sufficient capacity to complete the intervention) Exclusion Criteria: * Dementia or other major cognitive impairment * BMI \>32 (as increased subcutaneous fat prevents use of breathing measurement system) * Current smoker or smoked regularly within last 6 months * Any cardiorespiratory disease that requires medical intervention (except asthma management) * Currently receiving physiotherapy-based treatment for LC or breathing pattern disorder * Significant respiratory co-morbidity (e.g. COPD, uncontrolled Asthma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 Respiration Disorders respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID Respiratory disease

Contacts and locations

Locations

  • University of Salford

    Manchester, Greater Manchester, M6 6PU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.